JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on August 24, 2004; DOI: 10.1124/jpet.104.073718


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.073718v1
312/1/214    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jin, Y.-R.
Right arrow Articles by Yun, Y.-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jin, Y.-R.
Right arrow Articles by Yun, Y.-P.


Received for publication July 8, 2004.
Revised August 16, 2004.
Accepted for publication August 17, 2004.

Antiplatelet Activity of J78, An Antithrombotic Agent, Is Mediated by TXA2 Receptor Blockade with TXA2 Synthase Inhibition and Suppression of Cytosolic Ca2+ Mobilization

Yong-Ri Jin 1, Mi-Ra Cho 1, Chung-Kyu Ryu 2, Jin-Ho Chung 3, Dong-Yeon Yuk 4, Jin-Tae Hong 1, Kyung-Sup Lee 1, Jung-jin Lee 1, Mi-Yea Lee 4, Yong Lim 1, Yeo-Pyo Yun 1*

1 Chungbuk National University 2 Ewha Womans University 3 Seoul National University 4 Research Center for Bioresource and Health, Chungbuk National University

* Address correspondence to: E-mail: ypyun{at}chungbuk.ac.kr

Abstract

We previously reported that 2-chloro-3-[2'-bromo, 4'-fluoro-phenyl]-amino-8-hydroxy-1,4-naphthoquinone (J78), a newly synthesized 1,4-naphthoquinone derivative, exhibited a potent antithrombotic effect, which might be due to antiplatelet rather than anticoagulation activity. In the present study, possible antiplatelet mechanism of J78 was investigated. J78 concentration-dependently inhibited rabbit platelet aggregation induced by collagen (10 µg/ml), thrombin (0.05 U/ml), arachidonic acid (100 µM) and U46619 (9,11-dideoxy-9,11-methanoepoxy-prostaglandin F2,1 µM), a thromboxane (TX) A2 mimic, with IC50 values of 0.32 ± 0.01, 0.44 ± 0.02, 0.50 ± 0.04 and 0.36 ± 0.02 µM, respectively. J78 also produced a shift to the right of the concentration-response curve of U46619, indicating an antagonistic effect on TXA2 receptor. J78 concentration-dependently inhibited collagen-induced arachidonic acid liberation. In addition, J78 potently suppressed TXA2 formation by platelets that were exposed to arachidonic acid in a concentration-dependent manner, but had no effect on the production of PGD2, indicating an inhibitory effect on TXA2 synthase. This was supported by a TXA2 synthase activity assay that J78 concentration-dependently inhibited TXB2 formation converted from PGH2. Furthermore, J78 was also able to inhibit the [Ca2+]i mobilization induced by collagen or thrombin at such a concentration that completely inhibited platelet aggregation. Taken together, these results suggest that the antiplatelet activity of J78 may be mediated by TXA2 receptor blockade with TXA2 synthase inhibition and suppression of cytosolic Ca2+ mobilization.


Key words: 1,4-naphthoquinone, J78, TXA2 receptor, TXA2 synthase, [Ca2+]i mobilization, antiplatelet


This article has been cited by other articles:


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
P. Cong, Z.-L. Xiao, P. Biancani, and J. Behar
Prostaglandins mediate tonic contraction of the guinea pig and human gallbladder
Am J Physiol Gastrointest Liver Physiol, January 1, 2007; 292(1): G409 - G418.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.